Ligand Pharmaceuticals Q3 2026 Earnings Date & Estimates

Ligand Pharmaceuticals (NASDAQ:LGND) is a biopharmaceutical company that develops and licenses technologies and drug assets to pharmaceutical and biotechnology partners. Rather than operating primarily as a traditional commercial drug manufacturer, Ligand focuses on building a portfolio of royalty agreements, licensing arrangements and other partnerships that can generate payments when partnered products are developed, approved and sold.

The company’s best-known technology is Captisol, a chemically modified cyclodextrin designed to improve the solubility, stability and delivery of certain drug compounds. Captisol has been incorporated into multiple approved medicines, including Kyprolis (carfilzomib), Evomela (melphalan) and Veklury (remdesivir). Ligand also has rights to royalties and other economic interests associated with a range of partnered pharmaceutical products and drug-development programs.

Founded in 1987 and headquartered in San Diego, California, Ligand serves the global biopharmaceutical industry through collaborations with companies operating in the United States and international markets. Its partners are generally responsible for clinical development, regulatory submissions, manufacturing and commercialization, while Ligand participates through licensing fees, milestone payments and royalties tied to the success of partnered products.